Supplements and Compounds Library
Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 97–120 of 328
Probiotic Lactiplantibacillus plantarum OL3246 supports healthy aging by enhancing quality of life, reducing inflammation, and modulating gut microbiota: a pilot study
A pilot study demonstrates that Lactiplantibacillus plantarum OL3246 improves quality of life in aging adults through measurable reductions in inflammatory markers and shifts in gut microbiota composition. This probiotic strain shows potential as a targeted intervention for mitigating age-related inflammatory decline.
Rhythm posts first FDA approval for acquired hypothalamic obesity
IMCIVREE (setmelanotide) received FDA approval as the first therapy for acquired hypothalamic obesity, a rare condition where brain injury disrupts hunger and energy regulation. The Phase 3 TRANSCEND trial demonstrated an 18.4% BMI reduction versus placebo at 52 weeks, addressing a previously untreated disorder that causes relentless weight gain despite behavioral intervention.
Duodenal remodeling sustains weight loss after GLP-1 cessation
The Revita procedure, an endoscopic duodenal remodeling intervention, preserved 78% of GLP-1-induced weight loss one year after drug discontinuation, with one-third of participants continuing to lose weight. This addresses a clinical limitation of GLP-1 therapy: rapid weight rebound upon cessation, positioning mechanical intervention as a potential bridge to sustained metabolic change.
CSPC’s monthly weight-loss shot advances to US trials
CSPC Pharmaceutical's SYH2082, a once-monthly GLP-1/GIP receptor agonist, has received FDA approval to begin US clinical trials. The extended dosing interval addresses a critical barrier to treatment adherence that weekly alternatives have not solved, with potential implications for sustainable weight management and metabolic disease prevention.
Aging Triggers an Intestinal Energy Crisis and HDL3 Deficiency Disrupting Gut–Liver Axis Homeostasis
Aging impairs intestinal mitochondrial energy production, reducing HDL3 synthesis and disrupting the gut-liver axis, allowing inflammatory lipopolysaccharide to damage the liver. NMN restores NAD+ availability, rebuilds HDL3 production, and reverses this age-related hepatic injury in experimental models.
Monthly obesity shot moves closer to reality
MBX Biosciences reported early Phase 1 data for MBX 4291, a monthly injection designed to deliver steady drug release with reduced gastrointestinal side effects compared to current weekly GLP-1 treatments. The approach addresses a critical barrier to treatment sustainability: adherence through improved tolerability and dosing convenience.
MBX Biosciences reports 7% weight loss in preliminary Phase 1 trial of MBX 4291
MBX Biosciences reports 7% mean weight loss over eight weeks with MBX 4291, a GLP-1/GIP co-agonist prodrug, in a preliminary Phase 1 cohort with favorable tolerability. The pharmacokinetic profile supports once-monthly dosing, positioning this approach as a potential alternative to existing weekly GLP-1 therapeutics for weight management.
Multi‐Omics Reveals Mechanisms of Metabolic Rejuvenation in Aged Mice and Pre‐Frail Older Men by Losartan
Losartan, an angiotensin II receptor blocker, partially reversed aging-related metabolomic signatures in both aged mice and pre-frail older men, with effects dependent on functional angiotensin II receptors and correlating with improved survival in treated mice. The drug produced dose-dependent metabolic rejuvenation in humans and normalized age-related shifts in circulating metabolites, particularly lipids and amino acids.
RNA Recycling Extends Lifespan
RNASEK, an enzyme that degrades circular RNA accumulation in cells, extends lifespan in model organisms by removing a form of molecular waste that accelerates aging. This identifies a specific degradation pathway central to cellular longevity.
RANKL Inhibition Reverses Bone Loss and Extends Lifespan
RANKL targeting—via genetic deletion or antibody neutralization—reverses bone loss, restores muscle function, and extends lifespan in a mouse model of Hutchinson-Gilford progeria. This suggests RANKL inhibition may address the accelerated tissue degeneration characteristic of this premature aging syndrome.
Kailera plots IPO to fuel obesity pipeline
Kailera Therapeutics, backed by $1.6 billion in funding, is pursuing an IPO to advance its GLP-1-based obesity drug pipeline, with ribupatide showing 18-23% weight loss in trials. The company's capital requirements reflect how quickly the competitive landscape has shifted—efficacy alone no longer differentiates; payers now demand real-world outcomes data and cost justification.
Building a ‘Swiss Army Knife’ longevity drug
LinkGevity is developing a small-molecule therapeutic targeting necrosis—uncontrolled cell death—as an upstream driver of multiple age-related diseases. By intervening at this central physiological node, the approach aims to address degenerative change across chronic conditions simultaneously rather than treating diseases individually.
Selective NMDA Antagonism Preserves Neural Function in Neurodegeneration
Lys Therapeutics secured €25 million to advance LYS241, a monoclonal antibody targeting pathological interactions between tissue plasminogen activator and NMDA receptors. The approach addresses blood-brain barrier dysfunction and neuroinflammation in Parkinson's disease and ischemic stroke by preserving normal receptor function while blocking disease-driving signaling.
Citrus Flavonoid Restores Liver Metabolic Aging
Hesperetin, a flavonoid found in citrus peels, activates a specific signaling pathway (Hmgcs2-Pparα-Cisd2) that slows hepatic aging in preclinical models. This mechanism links dietary compounds to mitochondrial function and metabolic regulation—core processes governing healthy lifespan.
Engineered Probiotic Preserves Muscle During GLP-1 Weight Loss
NorthStrive is conducting analytical characterization of EL-22, an engineered Lactobacillus casei designed to express myostatin inhibition and preserve skeletal muscle during GLP-1 weight loss. The flow cytometry study validates manufacturing consistency and supports regulatory readiness for this targeted intervention addressing a known metabolic consequence of rapid weight reduction.
Dual receptor agonist enters Phase 3 for fatty liver reversal
Altimmune has initiated Phase 3 testing of pemvidutide, a dual glucagon/GLP-1 receptor agonist, for metabolic dysfunction-associated steatohepatitis (MDASH). The compound represents a mechanistic approach to nonalcoholic fatty liver disease by simultaneously engaging two metabolic pathways implicated in hepatic fat accumulation and energy dysregulation.
The Mitochondrial NAD Transporter SLC25A51 in Adipocytes Regulates Adipose Tissue Mitochondrial Function and Systemic Metabolism During Aging
SLC25A51, a mitochondrial NAD transporter in fat cells, declines with age and directly regulates adipose tissue energy metabolism and systemic insulin sensitivity. Loss of this transporter accelerates metabolic disease phenotypes; its restoration protects against obesity and insulin resistance in aging.
Omada Health study finds greater fat loss, preserved muscle
A 12-week study of 245 adults with obesity found that Omada's GLP-1 Care Track program—combining pharmacotherapy with structured exercise, coaching, and digital tracking—achieved 1.8-fold greater weight loss and nearly threefold greater muscle preservation compared to GLP-1 monotherapy alone. This differential body composition outcome has direct implications for maintaining metabolic capacity and physical function during intentional weight reduction.
Insilico, Tenacia expand AI-driven CNS collaboration
Insilico Medicine and Tenacia Biotechnology are expanding their AI-driven collaboration to design small-molecule therapies for central nervous system disorders, with a focus on blood-brain barrier penetration. This partnership demonstrates how generative AI can accelerate drug discovery for neurological conditions, including a candidate targeting NLRP3 inflammation that has cleared FDA review for Parkinson's disease trials.
The Immunogenicity of Human Senescent Cells Is Dependent on the Senescence Inducer and Cell Type
Senescent cell immunogenicity varies substantially by cell type and the trigger that induced senescence. RAS-induced senescent myoblasts activated immune responses, while senescent fibroblasts, endothelial cells, and lung progenitors showed limited or no immunogenicity despite expressing senescence markers.
LINC01021 Accelerates Cellular Senescence in Primates
Researchers identified LINC01021, a primate-specific long non-coding RNA that accumulates with age and actively promotes cellular senescence by suppressing RBMX, a regulator of the p53 tumor suppressor pathway. This discovery reveals a primate-specific mechanism driving aging that does not exist in rodent models, with direct implications for understanding human senescence and potential therapeutic targeting.
D-pinitol extends the lifespan of Caenorhabditis elegans through integrated antioxidant defense, proteostasis, and autophagy signaling
D-pinitol, a naturally occurring inositol derivative, extends lifespan in C. elegans by coordinating three distinct cellular mechanisms: antioxidant defense, protein stability (proteostasis), and autophagy. This multi-pathway activation suggests a compound that addresses fundamental aging processes rather than targeting a single intervention point.
Morphofunctional Heterogeneity and Plasticity of Glioblastoma Cells Induced to Senescence by Temozolomide
Temozolomide-induced senescent glioblastoma cells exhibit dynamic morphological states with distinct survival mechanisms and drug sensitivities. This heterogeneity and plasticity have direct implications for how chemotherapy resistance develops and why combination senotherapeutic strategies may be necessary to prevent tumor recurrence.
Designs for Health launches NeuroCalm Peptide for gut-brain support
Designs for Health introduced NeuroCalm Peptide, combining a milk-derived peptide (Lactium) with a heat-treated Lactobacillus strain to modulate the gut-brain axis. Clinical evidence suggests the formulation may reduce perceived stress and salivary cortisol while supporting sleep quality and emotional resilience through microbiome and nervous system pathways.